Pasar al contenido principal

GENERACION DE UNA COLECCION DE ESFEROIDES ORGANOTIPICOS 3D Y DE MODELOS PDX DE LDCG COMPLETAMENTE ANOTADOS PARA LA EVALUACION PRECLINICA DE DISRUPTORES DEL LINK TUMOR-ESTROMA

PID2021-123039OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miguel|||0000-0003-0597-5811
  • Sàrrias, Lluís
  • Gorjón-de-Pablo, Gema
  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Camaló-Vila, Judith|||0000-0003-2692-5952
  • Gibert, Albert
  • Puig de la Bellacasa, Raimon|||0000-0001-8349-4082
  • Teixidó, Jordi|||0000-0002-2720-9811
  • Roué, Gaël|||0000-0003-0245-2257
  • Borrell, José I.|||0000-0001-9409-2919
  • Estrada-Tejedor, Roger|||0000-0002-2983-0492
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miquel
  • Sàrrias, Lluís
  • Gorjón de Pablo, Gema
  • Fernández-Serrano, Miranda
  • Camaló Vila, Judith
  • Puig de la Bellacasa, Raimon
  • Teixidó, Jordi
  • Roué, Gaël
  • Borrell, Jose I.
  • Estrada-Tejedor, Roger
  • Gibert-Bosch, Albert
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miquel
  • Sàrrias, Lluís
  • Gorjón de Pablo, Gema
  • Fernández-Serrano, Miranda
  • Camaló Vila, Judith
  • Puig de la Bellacasa, Raimon
  • Teixidó, Jordi
  • Roué, Gaël
  • Borrell, Jose I.
  • Estrada-Tejedor, Roger
  • Gibert-Bosch, Albert
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

RHOA Therapeutic Targeting in Hematological Cancers

  • Santos, Juliana|||0000-0003-4148-9570
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Sánchez Vinces, Salvador|||0000-0001-7041-6544
  • Roué, Gaël|||0000-0003-0245-2257
Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival, migration, adhesion and proliferation. Deregulated activity of RHOA has been linked to the growth, progression and metastasis of various cancer types. Recent cancer genome-wide sequencing studies have unveiled both RHOA gain and loss-of-function mutations in primary leukemia/lymphoma, suggesting that this GTPase may exert tumor-promoting or tumor-suppressive functions depending on the cellular context. Based on these observations, RHOA signaling represents an attractive therapeutic target for the development of selective anticancer strategies. In this review, we will summarize the molecular mechanisms underlying RHOA GTPase functions in immune regulation and in the development of hematological neoplasms and will discuss the current strategies aimed at modulating RHOA functions in these diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Editorial, The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma

  • Caillot, Mélody
  • Miloudi, Hadjer
  • Taly, Antoine
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Santos, Juliana C.
  • Ribeiro, Marcelo L.|||0000-0003-4529-7832
  • Maitre, Elsa
  • Saule, Simon
  • Roué, Gaël|||0000-0003-0245-2257
  • Jardin, Fabrice
  • Sola, Brigitte|||0000-0001-7278-9651
  • Miloudi, Hadjer
Exportin 1 (XPO1) is the main nuclear export receptor that controls the subcellular trafficking and the functions of major regulatory proteins. XPO1 is overexpressed in various cancers and small inhibitors of nuclear export (SINEs) have been developed to inhibit XPO1. In primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin's lymphoma (cHL), the XPO1 gene may be mutated on one nucleotide and encodes the mutant XPO1. To understand the impact of mutation on protein function, we studied the response of PMBL and cHL cells to selinexor, a SINE, and ibrutinib, an inhibitor of Bruton tyrosine kinase. XPO1 mutation renders lymphoma cells more sensitive to selinexor due to a faster degradation of mutant XPO1 compared to the wild-type. We further showed that a mistrafficking of p65 (RELA) and p52 (NFκB2) transcription factors between the nuclear and cytoplasmic compartments accounts for the response toward ibrutinib. XPO1 mutation may be envisaged as a biomarker of the response of PMBL and cHL cells and other B-cell hemopathies to SINEs and drugs that target even indirectly the NFκB signaling pathway.